WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206220
Description: AZD6918 is a novel potent and selective inhibitor of the Trk tyrosine kinases. AZD-6918 attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth.
MedKoo Cat#: 206220
Chemical Formula: C20H20F2N6O
Exact Mass: 398.1667
Molecular Weight: 398.4178
Elemental Analysis: C, 60.29; H, 5.06; F, 9.54; N, 21.09; O, 4.02
AZD-6918 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: AZD-6918; AZD6918; AZD 6918.
IUPAC/Chemical Name: (S)-5-Fluoro-2-[[1-(4-fluorophenyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]nicotinonitrile
InChi Key: QRAQXWWNHQMCBH-LBPRGKRZSA-N
InChi Code: InChI=1S/C20H20F2N6O/c1-11(2)29-18-9-17(27-28-18)25-20-16(22)8-14(10-23)19(26-20)24-12(3)13-4-6-15(21)7-5-13/h4-9,11-12H,1-3H3,(H3,24,25,26,27,28)/t12-/m0/s1
SMILES Code: N#CC1=C(N[C@H](C2=CC=C(F)C=C2)C)N=C(NC3=NNC(OC(C)C)=C3)C(F)=C1
The following data is based on the product molecular weight 398.4178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ. Trk inhibitor attenuates the
BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and
in vivo. Cancer Biol Ther. 2015;16(3):477-83. doi: 10.1080/15384047.2015.1016659.
PubMed PMID: 25700942; PubMed Central PMCID: PMC4623105.
2: Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. Role and
relevance of TrkB mutations and expression in non-small cell lung cancer. Clin
Cancer Res. 2011 May 1;17(9):2638-45. doi: 10.1158/1078-0432.CCR-10-3034. PubMed
PMID: 21242122; PubMed Central PMCID: PMC3086954.
Phase I clinical trial for AZD-6918 was started in 2009. However, AZD6918 was discontinued from development due to an unacceptable pharmacokinetic profile. Drug was discontinued in 2009.